Corona Updates

Bharat Biotech’s Covaxin phase 3 data shows 77.8 pc efficacy against COVID-19, says Lancet

Hyderabad (Telangana) [India]: Hyderabad-based Bharat Biotech on Friday announced that the Lancet peer-review confirmed the efficacy analysis of Bharat Biotech’s Covaxin.As per phase-three clinical trials data, Covaxin demonstrates 77.8 per cent efficacy against symptomatic COVID-19. “COVAXIN is the only COVID-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the delta variant at 65.2 per cent,” the official statement issued by Bharat Biotech said citing the study by the Lancet.“Efficacy analysis demonstrates Covaxin to be 77.8 per cent effective against symptomatic COVID-19, through evaluation of 130 confirmed cases, with 24 observed in the vaccine group versus 106 in the placebo group,” said the company’s statement.Further, it said that Covaxin will be 93.4 per cent effective against severe symptomatic COVID-19.“Safety analysis demonstrates adverse events reported were similar to placebo, with 12 per cent of subjects experiencing commonly known side effects and less…

Corona Updates TOP NEWS UPDATES

Will take another 4-5 months to publish phase 3 trials data of ZyCoV-D vaccine: Zydus Group MD

New Delhi [India]: Managing Director of Zydus Group Dr Sharvil Patel on Saturday said that his firm will soon apply for the Indian drug regulator’s approval to conduct trials of ZyCoV-D on children above 2 years and added that it will take another 4-5 months to publish the phase 3 data of the Covid vaccine. The Ahmedabad-based pharma company has received approval from the Drugs Controller General of India (DCGI) for ZyCOV-D, the world’s first and India’s indigenously developed DNA-based vaccine for COVID-19 which will be administered in humans including adults and children 12 years and above.However, the pharma company has not published phase 3 data of trials yet.“So, the full phase 3 data will show not only the efficacy of the vaccine but also the safety and long-term immunogenicity details which is at least followed up for the next 3-6 months. So, for…

TOP NEWS UPDATES

Bharat Biotech concludes phase 3 Covaxin trial, claims 77.8% efficacy against COVID 19

Hyderabad-based Bharat Biotech on Saturday concluded a final analysis for its vaccine Covaxin efficacy from phase-3 clinical trial claiming it to be 77.8 per cent effective against COVID-19. It also added that Covaxin gives 65.2 per cent protection against the SARS-CoV-2, B.1.617.2 Delta variant. “Efficacy analysis demonstrates Covaxin to be 77.8 per cent effective against symptomatic COVID-19, through evaluation of 130 confirmed cases, with 24 observed in the vaccine group versus 106 in the placebo group. Efficacy analysis demonstrates Covaxin to be 93.4 per cent effective against severe symptomatic COVID-19,” the company said. As per the company, safety analysis demonstrates adverse events reported were similar to placebo, with 12 per cent of subjects experiencing commonly known side effects and less than 0.5 per cent of subjects feeling serious adverse events. “Efficacy data demonstrates 63.6 per cent protection against asymptomatic COVID-19. Efficacy data demonstrates 65.2…